VolitionRx Announces Breakthrough in Finger-Prick Nucleosome Detection for Sepsis Testing
VolitionRx Limited (VNRX) announced a breakthrough in detecting nucleosomes using a finger-prick lateral flow prototype, which could enable rapid, decentralized sepsis testing. This development expands the potential market for the company's diagnostic technology beyond centralized labs. The test could be used in various settings, including at home, and is similar to self-administered tests like pregnancy or COVID-19 tests.
Topics: epigenetics lateral flow technology medical diagnostics point-of-care testing sepsis detection